Patient Report 2014
Patients would like to get a lot more help from pharma, and pharma would like to help patients get a lot more. For any other industry with a loyal customer base, this would be a dream scenario. James Chase explores the disconnect
Social media monitoring offers more than just a snapshot of what patients are saying about your products. With the proper analysis, it can help get your launch back on track. Ernst & Young's Ric Cavieres and Karntipa Pisalyaput explain using a fictitious brand, Hilodax
Five industry experts discuss what it's really going to take to put the patients at the top of the healthcare pyramid
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.